UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________
FORM 6-K
______________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of January 2022
Commission File Number: 001-39992
______________________________
Immunocore Holdings plc
(Translation of registrant’s name into English)
______________________________
92 Park Drive
Milton Park
Abingdon, Oxfordshire OX14 4RY
United Kingdom
(Address of principal executive office)
______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
Press Release
On January 26, 2022, Immunocore Holdings plc announced approval from the U. S. Food and Drug Administration of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 6-K.
Exhibit No. | | Description |
| | | |
| | Press Release dated January 26, 2022. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | IMMUNOCORE HOLDINGS PLC |
| | | |
| Date January 26, 2022 | By: | /s/ Bahija Jallal, Ph.D. |
| | | Name | Bahija Jallal, Ph.D. |
| | | Title: | Chief Executive Officer |
